Drug intelligence / Profile preview

maytansinol

Development stage
Preclinical
Lead developer
SuviCa
Modality
Small Molecules
Administration
Oral, Subcutaneous, Intraperitoneal, Intravenous, Intramuscular
01

Overview

Maytansinol is a cytotoxic macrolide and the parent alcohol of the maytansinoid family of compounds. Originally isolated from plants of the genus *Maytenus*, it acts as a potent microtubule inhibitor by binding to tubulin at the maytansine site, which is distinct from but overlaps with the vinca alkaloid binding site. This binding inhibits microtubule assembly, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. While maytansinol itself is primarily used as a reference compound in research—such as in Drosophila cancer models studied by SuviCa—its most significant clinical application is as a precursor for the synthesis of thiol-containing maytansinoids like DM1 (mertansine) and DM4. These derivatives serve as the cytotoxic payloads for various antibody-drug conjugates (ADCs), enabling the targeted delivery of highly potent tubulin inhibitors to malignant cells.

Other names
Maytansin-9-olMaytansin9-olMaytansin 9-ol9-hydroxymaytansine
02

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on maytansinol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on maytansinol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call